ArticleBMC cancer2025
Diagnostic value of high-frame-rate contrast-enhanced ultrasound and contrast vector imaging for superficial lymph node lesions.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predicting lateral cervical lymph node involvement in papillary thyroid carcinoma patients: development of a nomogram model based on contrast-enhanced ultrasound images.Gland surgery · 2026Article
- Diagnostic value of high-frame-rate contrast-enhanced ultrasound and nomogram model in lymphomas.BMC cancer · 2025Article
- Ultrafast ultrasound localization microscopy for differential diagnosis of reactive hyperplasia and metastatic cervical lymph nodes: a pilot study.Quantitative imaging in medicine and surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore the diagnostic performance and feasibility of high-frame-rate contrast-enhanced ultrasound (HFR CEUS) combined with contrast vector imaging (CVI) in detecting benign and malignant superficial lymph nodes (SLNs). MATERIALS AND
methodsIn this single-center prospective study conducted between October 2023 and February 2024, 38 consecutive patients with suspected SLN lesions underwent B-mode US, HFR CEUS examination, and post-processing CVI analysis. Their diagnosis was confirmed using fine-needle aspiration cytologic or histopathologic examination. The diagnostic efficacy of HFR CEUS alone and the combination of HFR CEUS with CVI for benign and malignant LN diagnosis was compared and the significance of other CVI parameters was evaluated.
resultsThe final data set included 38 participants (mean age, 56 ± 16 years) with 42 SLN lesions. Both HFR CEUS alone and HFR CEUS combined with CVI examination showed differences in the contrast patterns of benign and malignant SLNs (all P < 0.001). The contrast pattern of benign LNs was predominantly centrifugal, while that of malignant LNs was primarily centripetal and hybrid and they were more likely to exhibit perfusion defects. The comparison between CVI combined with HFR CEUS examination and pathological results for the diagnosis of benign and malignant LNs showed a high level of consistency with a kappa value of 0.81. Comparison with HFR CEUS alone resulted in a kappa value of 0.66.
conclusionHFR CEUS combined with CVI examination demonstrated a good performance in distinguishing benign and malignant SLNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.